Somapacitan weekly dosing compared to daily Norditropin for pediatric growth hormone deficiency and short stature

Children suffering from growth hormone deficiency (GHD), Turner Syndrome, Noonan Syndrome, or idiopathic short stature often require long-term growth hormone (GH) therapy. The current standard of care typically involves daily subcutaneous injections, which can be burdensome for both children and their families, leading to compliance issues. Developing a less frequent dosing regimen, such as a once-weekly injection, could significantly improve patient adherence and quality of life, addressing a critical unmet need in pediatric endocrinology.

This Phase 3, randomized clinical trial (NCT04970654) enrolled 110 children with conditions like growth hormone deficiency, Turner Syndrome, Noonan Syndrome, or idiopathic short stature. Participants were randomly assigned to one of two treatment arms: either somapacitan once a week for up to 5.5 years, or Norditropin® once a day for 1 year followed by somapacitan once a week for up to 4.5 years. The study's primary objective was to compare the efficacy and safety of once-weekly somapacitan against daily Norditropin® in promoting growth.

As of the provided information, specific efficacy and safety results from this completed Phase 3 trial comparing Somapacitan and Norditropin® in pediatric populations are not yet published. The study aimed to assess primary endpoints such as annualized height velocity (AHV) and changes in height standard deviation score (HSDS), alongside comprehensive safety profiles including adverse events (AEs) and immunogenicity. While the trial concluded in December 2023, the detailed findings regarding Somapacitan's performance relative to daily Norditropin® are pending public disclosure. Future publications will reveal whether the weekly regimen achieved non-inferiority or superiority in growth parameters and demonstrated a comparable safety profile. The trial's completion suggests that data analysis is underway, and results are anticipated to be shared in scientific forums or peer-reviewed journals. The study design implies a focus on demonstrating that a less frequent dosing schedule can maintain similar growth outcomes and safety as the established daily therapy.